{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T13:52:52Z","timestamp":1772373172586,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Eumedica Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Temocillin is a carboxypenicillin antibiotic indicated in complicated urinary tract infections due to susceptible ESBL-producing Enterobacteriaceae. While temocillin therapeutic schemes for adult patients with normal or impaired renal function are evidence based, little is known in paediatric populations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>We report herein the management of temocillin treatment in a preterm infant with end-stage renal disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>The patient was a 7-month-old preterm infant born at 35\u2009weeks gestation and treated by temocillin for 10\u2009days for a bacteraemic urinary tract infection due to a susceptible ESBL-producing Enterobacter cloacae complex strain. Temocillin was administered by continuous infusion using a loading dose of 25\u2009mg followed by a maintenance dose of 70\u2009mg daily. Determination of MIC and temocillin plasma and urinary concentration was performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Clinical improvement was observed 24\u2009h after the initiation of temocillin treatment. Temocillin concentrations ranged between 21.6 and 35.5\u2009mg\/L in urine between the first and the sixth day of treatment and between 47.0 and 61.8\u2009mg\/L in plasma after 6 and 10\u2009days of treatment, respectively. Temocillin concentrations were found to be above the determined MIC of 6\u2009mg\/L. From the measured concentrations, we can postulate that 100%fT&amp;gt;MIC was achieved in urine and at least equal to 40% in plasma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Temocillin dosing adjustment performed in the present reported case allowed safe and effective treatment. The strategy described herein could be used as a basis for further clinical studies relative to temocillin use in a paediatric population with renal impairment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa356","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T19:14:39Z","timestamp":1595531679000},"page":"3652-3655","source":"Crossref","is-referenced-by-count":5,"title":["Temocillin dosage adjustment in a preterm infant with severe renal disease: a case report"],"prefix":"10.1093","volume":"75","author":[{"given":"Guillaume","family":"Dumangin","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, CHRU-Nancy, Department of Clinical Pharmacology and Toxicology, F-54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Brenkman","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, CHRU-Nancy, Department of Clinical Pharmacology and Toxicology, F-54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Pape","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, CHRU-Nancy, Department of Clinical Pharmacology and Toxicology, F-54000 Nancy, France"},{"name":"Universit\u00e9 de Lorraine, CNRS, IMoPA, F-54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan","family":"Kolodziej","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, CHRU-Nancy, Department of Clinical Pharmacology and Toxicology, F-54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Gambier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, CHRU-Nancy, Department of Clinical Pharmacology and Toxicology, F-54000 Nancy, France"},{"name":"Universit\u00e9 de Lorraine, CNRS, IMoPA, F-54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Vrillon","sequence":"additional","affiliation":[{"name":"CHRU-Nancy, Department of Pediatric Nephrology, F-54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Charmillon","sequence":"additional","affiliation":[{"name":"CHRU-Nancy, Department of Infectious and Tropical Diseases, F-54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9863-9739","authenticated-orcid":false,"given":"Julien","family":"Scala-Bertola","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, CHRU-Nancy, Department of Clinical Pharmacology and Toxicology, F-54000 Nancy, France"},{"name":"Universit\u00e9 de Lorraine, CNRS, IMoPA, F-54000 Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"2020111305061622300_dkaa356-B1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020111305061622300_dkaa356-B2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40262-017-0584-7","article-title":"Pharmacokinetics and pharmacodynamics of temocillin","volume":"57","author":"Alexandre","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2020111305061622300_dkaa356-B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/BF02148656","article-title":"Interpretive criteria for temocillin disk diffusion susceptibility testing","volume":"4","author":"Fuchs","year":"1985","journal-title":"Eur J Clin Microbiol"},{"key":"2020111305061622300_dkaa356-B4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/fmb-2018-0316","article-title":"Temocillin: is this the right momentum for its global use?","volume":"14","author":"Balakrishnan","year":"2019","journal-title":"Future Microbiol"},{"key":"2020111305061622300_dkaa356-B5","year":"2020"},{"key":"2020111305061622300_dkaa356-B6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2165\/00003495-198500295-00048","article-title":"Temocillin treatment of serious infections due to Gram-negative bacilli in an intensive care unit","volume":"29 Suppl 5","author":"Offenstadt","year":"1985","journal-title":"Drugs"},{"key":"2020111305061622300_dkaa356-B7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jac\/dkm467","article-title":"Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection","volume":"61","author":"De Jongh","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2020111305061622300_dkaa356-B8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020111305061622300_dkaa356-B9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.purol.2017.07.242","article-title":"Temocillin and urinary tract infections","volume":"27","author":"Vall\u00e9e","year":"2017","journal-title":"Prog Urol"},{"key":"2020111305061622300_dkaa356-B10","doi-asserted-by":"crossref","first-page":"4.","DOI":"10.1186\/s40360-016-0054-0","article-title":"Two case reports of the successful eradication of new isolates of Burkholderia cepacia complex in children with cystic fibrosis","volume":"17","author":"Kitt","year":"2016","journal-title":"BMC Pharmacol Toxicol"},{"key":"2020111305061622300_dkaa356-B11","first-page":"171","article-title":"Temocillin in the treatment of pyelonephritis in children","volume":"13","author":"Verboven","year":"1987","journal-title":"Drugs Exp Clin Res"},{"key":"2020111305061622300_dkaa356-B12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2020111305061622300_dkaa356-B13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/jac\/11.4.349","article-title":"The pharmacokinetics of temocillin in patients with normal and impaired renal function","volume":"11","author":"Boelaert","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"2020111305061622300_dkaa356-B14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/12.1.47","article-title":"Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function","volume":"12","author":"Leroy","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"2020111305061622300_dkaa356-B15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jac\/11.5.481","article-title":"Temocillin elimination in patients with varying degrees of renal failure","volume":"11","author":"Wright","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"2020111305061622300_dkaa356-B16","doi-asserted-by":"crossref","first-page":"104.","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with \u03b2-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise De Pharmacologie et Th\u00e9rapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation-SFAR","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/12\/3652\/34291437\/dkaa356.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/12\/3652\/34291437\/dkaa356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T10:06:37Z","timestamp":1605261997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/12\/3652\/5894666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,8,20]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa356","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,8,20]]}}}